Health
Excel
Mental Disorders Dataset – Psychiatric & Psychological Conditions
Mental Disorders Dataset
The Mental Disorders Dataset is a structured medical database containing a comprehensive list of psychiatric and psychological conditions affecting mental health and behaviour.
Mental health disorders such as depression, anxiety, bipolar disorder, and schizophrenia affect millions of people worldwide and are a major focus of modern healthcare and public health initiatives.
This dataset provides organised information about mental health conditions, helping researchers, developers, and healthcare professionals analyse symptoms, severity, and treatment approaches.
Each record includes detailed clinical information such as disorder descriptions, affected mental or neurological systems, common symptoms, severity levels, and typical management strategies.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for mental health researchers, healthcare developers, educators, and data scientists working with psychological and psychiatric data.
Dataset Contents
The dataset includes fields such as:
- Disorder Name
- Description
- Affected System (Psychological / Neurological)
- Common Symptoms
- Severity Level
- Disorder Category
- Risk Factors
- Treatment / Management
Example Conditions Included
- Depression (Major Depressive Disorder)
- Anxiety Disorders
- Bipolar Disorder
- Schizophrenia
- Post-Traumatic Stress Disorder (PTSD)
- Obsessive-Compulsive Disorder (OCD)
- Eating Disorders
- Attention Deficit Hyperactivity Disorder (ADHD)
- Autism Spectrum Disorder
- Personality Disorders
...and many more mental health conditions.
Data Preview
17 columns
25 rows shown
| ID | Disease Name | Category | Prevalence | Inheritance Pattern | Affected Gene(s) | Chromosome Location | Key Symptoms | Typical Age of Onset | Diagnosis Methods | Available Treatments | Orphan Drug Designation | ICD-10 Code | OMIM Number | Affected System | Disease Severity | Life Expectancy Impact | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | Mild Intellectual Developmental Disorder | Neurodevelopmental | ~0.5-0.8% general population (DSM-5-TR); ~85% of all intellectual disability cases | Variable (polygenic / de novo / environmental) | Polygenic; many genes including CNVs | Multiple loci | IQ ~50-69, conceptual learning delays, impaired social judgment, reading/writing below grade level, slower academic progress, some adaptive skill limitations, can live independently with support | Childhood (before age 18) | DSM-5-TR: deficits in intellectual + adaptive functioning; Wechsler/Stanford-Binet IQ; Vineland-3, ABAS-3; onset in developmental period | Special education, behavioral therapy, vocational training, family support; no disease-modifying drug | No | F70 | N/A | CNS / Cognitive / Adaptive | Mild | Slightly reduced |
| 2 | 2 | Moderate Intellectual Developmental Disorder | Neurodevelopmental | ~0.1-0.3% population (~10% of ID cases) | Variable (genetic syndromes common: Down, Fragile X, FAS) | Multiple (trisomy 21, FMR1, others) | Multiple loci (often 21q, Xq27.3) | IQ ~35-49, marked language delay, basic self-care with support, supervised employment feasible, academic ceiling ~2nd grade, needs ongoing social support | Infancy/early childhood | DSM-5-TR adaptive + IQ criteria; karyotype, chromosomal microarray, FMR1 testing, metabolic screen, brain MRI | Early intervention, speech/OT/PT, behavioral therapy, supported living, manage comorbidities | No | F71 | N/A | CNS / Cognitive / Adaptive | Moderate | Moderately reduced |
| 3 | 3 | Severe Intellectual Developmental Disorder | Neurodevelopmental | ~0.03-0.04% population (~3.5% of ID) | Variable (usually identifiable genetic/metabolic cause) | Multiple | Multiple loci | IQ ~20-34, minimal speech, requires assistance with all ADLs, significant motor impairment, frequent seizures, limited academic skills, fully dependent | Infancy | DSM-5-TR criteria; comprehensive genetic panel, metabolic workup, EEG, MRI brain | Intensive support, AAC devices, PT/OT, seizure management, feeding support | No | F72 | N/A | CNS / Cognitive | Severe | Moderately to severely reduced |
| 4 | 4 | Profound Intellectual Developmental Disorder | Neurodevelopmental | ~0.01-0.05% population (~1-2% of ID) | Usually syndromic/genetic | Often structural brain anomalies + single-gene disorders | Multiple loci | IQ <20, conceptual skills limited to physical world, minimal/no verbal communication, fully dependent, severe seizures, feeding difficulty, sensory and motor impairments | Infancy | DSM-5-TR criteria; whole exome sequencing, neuroimaging, metabolic, EEG | 24-hour care, seizure management, G-tube feeding, orthopedic care, palliative approach | Sometimes | F73 | N/A | CNS / Cognitive / Motor | Severe | Severely reduced |
| 5 | 5 | Global Developmental Delay | Neurodevelopmental | ~1-3% of children under age 5 | Variable | Varies (genetic, acquired, idiopathic) | Multiple loci | Failure to meet multiple developmental milestones (motor, speech, cognitive, social), hypotonia often present, delayed walking/talking, used when child too young for reliable IQ testing | Before age 5 | DSM-5-TR: delays in >=2 domains in child too young for IQ testing; chromosomal microarray, FMR1, metabolic, MRI | Early intervention, PT/OT/speech therapy, family support, address etiology | No | F88 | N/A | CNS / Neurodevelopmental | Variable | Variable |
| 6 | 6 | Language Disorder | Neurodevelopmental | ~7% school-age children (DSM-5-TR) | Polygenic (heritable ~50-70%) | CNTNAP2, FOXP2, others | Multiple loci (7q31 etc.) | Reduced vocabulary, limited sentence structure, discourse impairment, difficulty following directions, word-finding problems, grammatical errors | Early childhood | DSM-5-TR criteria; CELF-5, PLS-5, audiological evaluation | Speech-language therapy, parent training, classroom accommodations | No | F80.2 | N/A | CNS / Language | Mild to Moderate | None |
| 7 | 7 | Speech Sound Disorder | Neurodevelopmental | ~8-9% children age 4-6 | Polygenic | FOXP2 and others | 7q31 and others | Difficulty with speech sound production, unintelligibility, sound substitution/omission/distortion, affects communication | Early childhood (age 3-6) | DSM-5-TR criteria; GFTA-3 articulation testing, oral-motor exam, audiogram | Articulation therapy, phonological intervention | No | F80.0 | N/A | CNS / Speech motor | Mild | None |
| 8 | 8 | Childhood-Onset Fluency Disorder (Stuttering) | Neurodevelopmental | ~1% in adults (~5% at some point in childhood) | Polygenic/heritable (~80% heritability) | GNPTAB, GNPTG, NAGPA, AP4E1 | 12q, 16q and others | Sound/syllable repetitions, prolongations, blocks, word avoidance, secondary behaviors, situational variation, onset age 2-6 | Early childhood (ages 2-7) | DSM-5-TR criteria; SSI-4 fluency assessment | Lidcombe program, fluency shaping, CBT, SLP therapy | No | F80.81 | N/A | CNS / Speech motor | Mild to Moderate | None |
| 9 | 9 | Social (Pragmatic) Communication Disorder | Neurodevelopmental | ~0.5-1% (often under-recognized) | Polygenic | Overlap with ASD genetics | Multiple loci | Deficits in social communication, impaired conversation, difficulty with narrative, literal interpretation, NOT meeting ASD restricted/repetitive criteria | Early childhood (age 4-5) | DSM-5-TR criteria; rule out ASD; CASL-2 | Social communication therapy, SLP, social skills training | No | F80.82 | N/A | CNS / Social communication | Mild to Moderate | None |
| 10 | 10 | Autism Spectrum Disorder | Neurodevelopmental | ~1 in 36 US children / ~2.8% (CDC ADDM 2023); ~1-2% worldwide | Highly polygenic + de novo CNVs (~80% heritability) | SHANK3, CHD8, SCN2A, NRXN1, MECP2, TSC1/2, hundreds more | Multiple loci | Persistent deficits in social communication, restricted/repetitive behaviors, sensory sensitivities, insistence on sameness, stereotyped movements, atypical language, intense focused interests | Early childhood (before age 3) | DSM-5-TR criteria; ADOS-2, ADI-R, M-CHAT-R, chromosomal microarray, Fragile X testing | Early intensive behavioral intervention (ABA, ESDM), speech/OT; FDA-approved risperidone and aripiprazole for irritability | No | F84.0 | 209850 | CNS / Neurodevelopmental | Variable | Slightly to moderately reduced |
| 11 | 11 | ADHD, Combined Presentation | Neurodevelopmental | ~5-7% children, ~2.5-4% adults (DSM-5-TR); most common subtype | Polygenic (heritability ~74%) | 27+ GWAS loci (DRD4, DRD5, DAT1, LPHN3, FOXP2) | Multiple loci | Inattention (6+) AND hyperactivity-impulsivity (6+), onset <12, >=2 settings, executive dysfunction, emotional dysregulation, forgetfulness, fidgeting | Childhood (symptoms before age 12) | DSM-5-TR criteria; Vanderbilt/Conners rating scales | Stimulants (methylphenidate, amphetamines), non-stimulants (atomoxetine, guanfacine, viloxazine/Qelbree Apr 2021), behavioral therapy | No | F90.2 | 143465 | CNS / Executive function | Moderate | Slightly reduced |
| 12 | 12 | ADHD, Predominantly Inattentive Presentation | Neurodevelopmental | ~2-3% school-age children; more common in females | Polygenic (heritability ~74%) | Shared ADHD loci | Multiple loci | Difficulty sustaining attention, careless mistakes, poor organization, avoids sustained mental effort, loses items, easily distracted, forgetful | Childhood | DSM-5-TR: >=6 inattentive symptoms (>=5 if 17+), <6 hyperactive symptoms, onset <12 | Stimulants, atomoxetine, behavioral interventions | No | F90.0 | 143465 | CNS / Executive function | Mild to Moderate | None |
| 13 | 13 | Specific Learning Disorder with Impairment in Reading (Dyslexia) | Neurodevelopmental | ~5-15% school-age children | Polygenic (heritability ~40-60%) | DYX1C1, KIAA0319, DCDC2, ROBO1 | 6p22, 15q21, others | Inaccurate/slow word reading, poor decoding, poor spelling, phonological processing deficits, reading comprehension affected, persistent despite intervention | Early school age (K-2nd grade) | DSM-5-TR: persistent difficulties >=6 months despite intervention; WJ-IV, WIAT-4 | Structured multisensory literacy (Orton-Gillingham), reading intervention, accommodations, assistive technology | No | F81.0 | 127700 | CNS / Reading/Language | Mild to Moderate | None |
| 14 | 14 | Specific Learning Disorder with Impairment in Written Expression | Neurodevelopmental | ~7-15% school-age children | Polygenic | Overlap with dyslexia genetics | Multiple loci | Poor spelling, grammar/punctuation errors, disorganized written expression, dysgraphia overlap, reduced written output, slow writing | Elementary school | DSM-5-TR criteria; TOWL-4, WIAT-4 | Writing intervention, keyboarding, speech-to-text, accommodations | No | F81.81 | N/A | CNS / Writing/Language | Mild to Moderate | None |
| 15 | 15 | Developmental Coordination Disorder | Neurodevelopmental | ~5-6% children ages 5-11 (DSM-5-TR) | Polygenic (heritable ~70%) | Candidate genes under investigation | Multiple loci | Clumsiness, poor motor coordination, handwriting difficulty, trouble with self-care, delayed milestones, poor balance, avoidance of sports | Early childhood (onset by age 5) | DSM-5-TR: motor skills below expected; Movement ABC-2, BOT-2 | Occupational therapy, physical therapy, task-oriented interventions, adaptive PE | No | F82 | N/A | CNS / Motor coordination | Mild to Moderate | None |
| 16 | 16 | Tourette's Disorder | Neurodevelopmental | ~0.3-0.9% children (DSM-5-TR); male:female ~3-4:1 | Polygenic (heritability ~77%) | SLITRK1, HDC, NRXN1, CELSR3 | Multiple loci (13q31, 2p, 17q25) | Multiple motor tics AND one or more vocal tics >1 year, onset <18, premonitory urges, waxing/waning, commonly comorbid with OCD and ADHD | Childhood (onset age 4-6, peak age 10-12) | DSM-5-TR criteria; Yale Global Tic Severity Scale | CBIT behavioral therapy, alpha-agonists (guanfacine, clonidine), antipsychotics (haloperidol, aripiprazole), VMAT2 inhibitors, DBS for refractory | No | F95.2 | 137580 | CNS / Movement | Variable | None |
| 17 | 17 | Rett Syndrome | Neurodevelopmental | ~1 in 10,000-15,000 female births; ~6,000-9,000 in US | X-linked dominant (most de novo, usually lethal in males) | MECP2 | Xq28 | Normal early development then regression (6-18 months), loss of purposeful hand use, hand wringing stereotypies, loss of spoken language, gait apraxia, seizures (60-80%), breathing irregularities, scoliosis | 6-18 months (after normal early development) | DSM-5-TR under NDD with specifier; MECP2 sequencing + deletion/duplication; RettSearch 2010 clinical criteria | Daybue/trofinetide (FDA 3/10/2023, first-ever for Rett); anticonvulsants, PT/OT/SLP, orthopedic, nutritional support | Yes | F84.2 | 312750 | CNS / Neurodevelopmental / Multisystem | Severe | Severely reduced |
| 18 | 18 | Fragile X Syndrome | Neurodevelopmental | ~1 in 4,000 males; ~1 in 6,000-8,000 females | X-linked (CGG repeat expansion >200 in FMR1) | FMR1 | Xq27.3 | Intellectual disability (most common inherited cause), elongated face, large ears, macroorchidism post-puberty, hyperactivity, ASD features, anxiety, hand-flapping, joint hyperlaxity, seizures (~20%) | Infancy/early childhood | DSM-5-TR ID criteria + FMR1 CGG repeat testing, methylation analysis | Early intervention, special education, SSRIs for anxiety, stimulants for ADHD, antipsychotics for irritability; no disease-modifying therapy approved | Yes | Q99.2 | 300624 | CNS / Neurodevelopmental | Moderate to Severe | Slightly reduced |
| 19 | 19 | Delirium | Neurocognitive | ~18-35% hospitalized elderly; up to 82% ICU; ~1-2% community elderly | Acquired | N/A | N/A | Acute disturbance in attention/awareness, fluctuating course (hours-days), cognitive disturbance (memory, orientation, language, perception), evidence of medical/substance cause, perceptual disturbances | Any age (most common in elderly, postoperative, critically ill) | DSM-5-TR criteria; CAM, CAM-ICU; identify underlying cause (infection, metabolic, drug, hypoxia) | Treat underlying cause, reorientation, sleep-wake cycle management, minimize deliriogenic drugs, haloperidol/quetiapine for severe agitation, avoid benzodiazepines | No | F05 | N/A | CNS / Cognitive (acute) | Variable | Moderately reduced |
| 20 | 20 | Major Neurocognitive Disorder due to Alzheimer's Disease | Neurocognitive | ~10-13% adults >=65; ~35% of >=85; ~6.7 million in US (2023) | Mostly sporadic; ~1% early-onset autosomal dominant; APOE e4 major risk factor | APP, PSEN1, PSEN2, APOE, TREM2, SORL1 | 21q21, 14q24, 1q42, 19q13 | Insidious progressive memory loss, impaired new learning, word-finding difficulty, visuospatial deficits, executive dysfunction, behavioral/psychological symptoms, functional decline, later apraxia/aphasia/agnosia | Usually after age 65 (early-onset <65 rare) | DSM-5-TR criteria; MMSE/MoCA, neuropsych testing, MRI (hippocampal atrophy), CSF Abeta42/tau, amyloid PET, plasma p-tau217 | Leqembi/lecanemab (FDA full approval 7/6/2023), Kisunla/donanemab (FDA 7/2/2024) for early AD; cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine; supportive care | No | G30.9 / F02.80 | 104300 | CNS / Cognitive | Severe | Severely reduced |
| 21 | 21 | Major Neurocognitive Disorder due to Frontotemporal Lobar Degeneration | Neurocognitive | ~15-22 per 100,000; common cause of early-onset dementia | ~30-50% familial; autosomal dominant forms | MAPT, GRN, C9orf72, VCP, CHMP2B, TBK1 | 17q21, 9p21, others | bvFTD: disinhibition, apathy, loss of empathy, compulsive behaviors, hyperorality, executive dysfunction; PPA variants (semantic, nonfluent, logopenic); relative early memory preservation | Age 45-65 | DSM-5-TR criteria; MRI (frontal/temporal atrophy), FDG-PET, genetic testing (C9orf72); Rascovsky/Gorno-Tempini criteria | Symptom management (SSRIs, trazodone), speech therapy for PPA; avoid cholinesterase inhibitors and antipsychotics; no disease-modifying therapy | Yes | G31.09 / F02.80 | 600274 | CNS / Cognitive / Behavioral | Severe | Severely reduced |
| 22 | 22 | Major Neurocognitive Disorder with Lewy Bodies | Neurocognitive | ~5% of dementias; second most common neurodegenerative dementia; ~1.4 million US | Mostly sporadic; rare familial | SNCA, SNCB, GBA (risk), APOE | 4q22, 5q35, 1q21 | Fluctuating cognition with variations in attention/alertness, recurrent detailed visual hallucinations, REM sleep behavior disorder, spontaneous parkinsonism, severe neuroleptic sensitivity, autonomic dysfunction, repeated falls | After age 50 (peak 70s) | DSM-5-TR criteria; McKeith 2017 consensus; DaT-SPECT, MIBG cardiac scintigraphy, polysomnography | Cholinesterase inhibitors (rivastigmine, donepezil), levodopa cautiously, melatonin/clonazepam for RBD, pimavanserin/quetiapine if needed, AVOID typical antipsychotics | No | G31.83 / F02.80 | 127750 | CNS / Cognitive / Motor / Autonomic | Severe | Severely reduced |
| 23 | 23 | Major Vascular Neurocognitive Disorder | Neurocognitive | Second most common dementia; ~15-20% of dementias; often mixed with AD | Acquired (vascular risk factors); rare genetic (CADASIL) | NOTCH3 (CADASIL), HTRA1 | 19p13 (CADASIL) | Stepwise cognitive decline, executive dysfunction predominant, gait disturbance, focal neurological signs, stroke/TIA history, vascular risk factors, urinary incontinence | After age 65 (earlier with CADASIL/stroke) | DSM-5-TR criteria; MRI showing infarcts/white matter disease, VASCOG/NINDS-AIREN criteria | Vascular risk management (BP, statins, antiplatelets, anticoagulation for AFib), smoking cessation, rehabilitation; cholinesterase inhibitors modest benefit | No | F01.50 | 125310 | CNS / Cognitive / Vascular | Severe | Moderately to severely reduced |
| 24 | 24 | Major Neurocognitive Disorder due to Traumatic Brain Injury | Neurocognitive | ~2-5% of dementia cases; ~2.5M TBI ED visits/yr in US | Acquired | N/A (APOE e4 worsens outcome) | N/A | Persistent cognitive impairment following TBI, executive dysfunction, memory loss, attention deficits, personality change, mood disturbance, headaches, slowed processing; CTE in repetitive TBI | Any age (after injury; CTE years-decades later) | DSM-5-TR criteria; onset temporally related to TBI; neuropsych testing, MRI/DTI, LOC/amnesia history | Cognitive rehabilitation, PT/OT/SLP, treat depression/PTSD, sleep management, methylphenidate for fatigue; no disease-modifying therapy | No | F02.80 | N/A | CNS / Cognitive / Multidomain | Variable | Slightly to moderately reduced |
| 25 | 25 | Major Neurocognitive Disorder due to HIV Infection | Neurocognitive | ~15-55% of people with HIV have HAND; ~2-8% severe/HAD | Acquired | N/A | N/A | Psychomotor slowing, impaired executive function and attention, memory deficits, apathy, gait instability, tremor, reduced verbal fluency, depression; less common with effective ART | Adulthood | DSM-5-TR criteria; HIV-positive confirmed, CD4 count, CSF HIV RNA, Frascati criteria, MRI to exclude OIs | ART with CNS penetration, adherence support, treat opportunistic infections, neurorehabilitation, SSRIs for depression | No | B20 / F02.80 | N/A | CNS / Cognitive | Moderate to Severe | Moderately reduced |
- Full dataset access
- Excel format
- Instant download